Generic Tavalisse Availability
Last updated on Sep 11, 2024.
Tavalisse is a brand name of fostamatinib, approved by the FDA in the following formulation(s):
TAVALISSE (fostamatinib disodium - tablet;oral)
-
Manufacturer: RIGEL PHARMS
Approval date: April 17, 2018
Strength(s): EQ 100MG BASE [RLD], EQ 150MG BASE [RLD]
Has a generic version of Tavalisse been approved?
No. There is currently no therapeutically equivalent version of Tavalisse available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tavalisse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,449,458
Patent expiration dates:
- September 4, 2031✓
- September 4, 2031
-
Patent 7,538,108
Patent expiration dates:
- March 28, 2026✓✓
- March 28, 2026
-
Patent 7,989,448
Patent expiration dates:
- June 12, 2026✓✓
- June 12, 2026
-
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Patent 8,163,902
Issued: April 24, 2012
Inventor(s): Bhamidipati Somasekhar & Singh Rajinder & Sun Thomas & Masuda Esteban
Assignee(s): Rigel Pharmaceuticals, Inc.The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Patent expiration dates:
- June 17, 2026✓✓
- June 17, 2026
-
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Patent 8,211,889
Issued: July 3, 2012
Inventor(s): Singh Rajinder & Bhamidipati Somasekhar & Sun Thomas & Stella Valentino J.
Assignee(s): Rigel Pharmaceuticals, Inc.The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Patent expiration dates:
- January 19, 2026✓
- January 19, 2026
-
Wet granulation using a water sequestering agent
Patent 8,263,122
Issued: September 11, 2012
Inventor(s): Sun Thomas & Lo Ray
Assignee(s): Rigel Pharmaceuticals, Inc.Disclosed are tablets comprising hydrolytically stable formulations of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt (Compound 1) prepared by a wet granulation process.
Patent expiration dates:
- November 24, 2030✓
- November 24, 2030
-
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Patent 8,445,485
Issued: May 21, 2013
Inventor(s): Bhamidipati Somasekhar & Singh Rajinder & Sun Thomas & Masuda Esteban
Assignee(s): Rigel Pharmaceuticals, Inc.The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Patent expiration dates:
- June 17, 2026✓
- June 17, 2026
-
Wet granulation using a water sequestering agent
Patent 8,652,492
Issued: February 18, 2014
Inventor(s): Sun Thomas & Lo Ray J.
Assignee(s): Rigel Pharmaceutical, Inc.Disclosed are tablets comprising hydrolytically stable formulations of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt (Compound 1) prepared by a wet granulation process.
Patent expiration dates:
- November 6, 2028✓
- November 6, 2028
-
(Trimethoxyphenylamino) pyrimidinyl formulations
Patent 8,771,648
Issued: July 8, 2014
Inventor(s): Gururajan Bindhumadhavan & Alhusban Farhan Abdul Karim & Gabbott Ian Paul & Simpson David Bradley Brook & Sievwright Dawn
Assignee(s): Rigel Pharmaceuticals, Inc.There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.
Patent expiration dates:
- July 27, 2032✓
- July 27, 2032
-
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Patent 8,912,170
Issued: December 16, 2014
Inventor(s): Bhamidipati Somasekhar & Singh Rajinder & Sun Thomas & Masuda Esteban
Assignee(s): Rigel Pharmaceuticals, Inc.The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Patent expiration dates:
- June 17, 2026✓
- June 17, 2026
-
(trimethoxyphenylamino) pyrimidinyl formulations
Patent 8,951,504
Issued: February 10, 2015
Inventor(s): Gururajan Bindhumadhavan & Alhusban Farhan Abdul Karim & Gabbott Ian Paul & Sievwright Dawn & Brook David Bradley
Assignee(s): Rigel Pharmaceuticals, Inc.There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.
Patent expiration dates:
- July 27, 2032✓
- July 27, 2032
-
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Patent 9,266,912
Issued: February 23, 2016
Inventor(s): Singh Rajinder & Bhamidipati Somasekhar & Masuda Esteban & Sun Thomas & Stella Valentino J.
Assignee(s): Rigel Pharmaceuticals, Inc.The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Patent expiration dates:
- January 19, 2026✓
- January 19, 2026
-
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Patent 9,283,238
Issued: March 15, 2016
Inventor(s): Bhamidipati Somasekhar & Singh Rajinder & Sun Thomas & Masuda Esteban
Assignee(s): Rigel Pharmaceuticals, Inc.The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Patent expiration dates:
- June 17, 2026✓
- June 17, 2026
-
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Patent RE48898
Issued: January 25, 2022
Inventor(s): Bhamidipati Somasekhar & Singh Rajinder & Sun Thomas & Masuda Esteban
Assignee(s): Rigel Pharmaceuticals, Inc.The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Patent expiration dates:
- January 19, 2026✓
- January 19, 2026
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 17, 2025 - FOR THE TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
More about Tavalisse (fostamatinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous coagulation modifiers
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
